Therefore, understanding the mechanisms that result in transient or nonpermanent amplifications of DHFR, EGFR, and alike in cancer (Table 1) will have a profound impact on how we view copy number control as well as how we identify novel biomarkers and therapeutic targets for treating drug-resistant cancers. The gene discussed is EGFR; the disease is cancer.